Navigation Links
ARISE INFUSION THERAPY SERVICES Now Infusing Ocrevustm (Ocrelizumab) For Relapsing and Primary Progressive Forms of Multiple Sclerosis

Written By: Ashley D. Beall, MD, FACR

Arise Infusion is pleased to now offer a major advancement in drug therapy for patients living with relapsing and primary multiple sclerosis that can significantly improve their lives. Ocrevus (pronounced Ah-creh-vus) is a novel B cell targeted therapy that has been proven to significantly reduce signs of disease activity and mitigate the progressive disability that individuals afflicted with this disease often experience. “This new biologic treatment provides hope for individuals that have not had any available FDA-approved therapies. We are committed to helping those who can benefit with access to this medication”, said Ashley Beall, MD, FACR, Medical Director of Arise Infusion.

OCREVUS became available to patients in the U.S. in March of this year after receiving FDA approval for the treatment of multiple sclerosis. OCREVUS is administered by intravenous infusion by a nurse and is only available at a licensed infusion center. The first dose is given as two 300 mg infusions two weeks apart. Subsequent doses are given as single 600 mg infusions every six months. Arise Infusion Therapy Services is one of the first infusion centers in the metropolitan Washington DC area to offer this treatment. Arise Infusion is committed to helping patients access this exciting new treatment by handling the pre-authorization process and helping to secure co-payment assistance for those in need.

About multiple sclerosis
Multiple sclerosis (MS) is a chronic disease for which there is currently no cure. MS affects an estimated 400,000 people in the U.S. The disease occurs when the body’s immune system attacks the insulation (myelin sheath) surrounding its own nerve cells in the brain, spinal cord and optic nerves, causing inflammation that disrupts nerve impulses. This damage can lead to a wide range of symptoms, including muscle weakness, fatigue and visual changes, and may eventually lead to disability. Most people with MS experience their first symptom between 20 and 40 years of age, making the disease the leading cause of non-traumatic disability in younger adults.  

ARISE INFUSION THERAPY SERVICES has five conveniently located centers in the Washington D.C. metropolitan area that provide safe and cost-effective infusion therapy.  Arise Infusion centers are modern and attractive with many amenities to ensure patients’ comfort.  Arise treats patients with auto-immune and inflammatory conditions who aren’t so sick that they need to be treated in a hospital and aren’t so frail that they require home care. Emphasizing a “safety first” philosophy, Arise Infusion centers are staffed with highly trained registered nurses working under physician supervision. The offices are bright, cheerful places where people come to manage their conditions so they can lead full and productive lives.

The Arise Infusion team helps to manage all issues related to insurance pre-authorization, payment arrangements, and scheduling to ensure a smooth and pleasant infusion experience.  

For more information regarding Arise Infusion visit our website at or call 240-514-5000.

Read the full story at

Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved

Related medicine news :

1. Highly drug resistant, virulent strain of Pseudomonas aeruginosa arises in Ohio
2. RE/MAX Agent Charise Goodnight Helps Children in Need Have a Good Day
3. Promising Results Arise from Phase 2 Vaccine Study for Mesothelioma
4. Magnesium Infusion: Review Examines Ian Clark's New Pure Magnesium Product
5. InfusionPoints, LLC Achieves ISO 9001:2008 Certification
6. Medtronic Infusion Pump Recall Lawyers: Resource4thePeople Announces Free Consultations Will Be Available over the Holidays
7. Transparency Market Research Adds Report on Global Infusion System Market to its Repository
8. Asia-Pacific Market for Infusion Therapy Devices Led by Terumo, JMS and Nipro Medical is expected to reach over $900 million by 2020
9. APAC Infusion Therapy Device Market Analysed and Forecast in New iData Research Study Available at
10. Infusion Pumps Market: An Overview of Growth Prospects and Market Restraints: Transparency Market Research
11. Global Medical Robotic Systems Market Will Be Driven By Infusion Of Technology In Medical Devices Industry From 2014 To 2020: Grand View Research, Inc.
Post Your Comments:
(Date:10/13/2017)... ... ... The American Board of Family Medicine's (ABFM) Board of Directors has selected Warren ... James C. Puffer upon his retirement. Dr. Newton will serve in the position of ... end of 2018. Upon assuming the role of President and CEO on January 1, ...
(Date:10/13/2017)... ... ... Lori R. Somekh, founder of the Law Office of Somekh & ... and special needs planning attorneys. “Membership in ElderCounsel helps our office remain up to ... with elder law attorneys nationwide,” said Somekh. , ElderCounsel was founded ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network ... advocate for action towards gender equality at their inaugural Summit in New York City ... and reached a social audience of over 3 million. To watch the Mobilize Women ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in ... awarded a contract by the Center for Medicare and Medicaid Services (CMS). The ... enterprise use of Agile methodologies in a consistent and high value manner across ...
(Date:10/12/2017)... San Francisco, CA (PRWEB) , ... October 12, ... ... and Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus ... sleep apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral ...
Breaking Medicine News(10 mins):
(Date:9/19/2017)... 19, 2017   ZirMed Inc ., a recognized leader ... that it has been ranked #1 by its users for ... Rankings 2017 User Survey. ZirMed was recognized as the top-ranked ... and medical centers over 200 beds and holds one of ... user survey history. ...
(Date:9/18/2017)... , Sept. 18, 2017 ... fields of bioinformatics and immune engineering, today ... protective avian influenza A (H7N9) vaccine. ... related to seasonal influenza and presents a ... on prior exposure to be effective. Using ...
(Date:9/12/2017)... YORK , Sept. 12, 2017   EcoVadis , the leading ... has published the first annual edition of its Global CSR Risk and ... companies evaluated by EcoVadis, based on Scorecard Ratings that analyzed nearly 800,000 ... ... Index ...
Breaking Medicine Technology: